Coronado Reports Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis

Coronado Biosciences, Inc.

, a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of a National Institutes of Health (NIH)-sponsored phase 2 study evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of ulcerative colitis (UC). This multi-center study will be conducted by the Autoimmunity Centers of Excellence (ACE), which are funded through a multi-million dollar grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.